logo
  

Merck Presents Positive Results From Phase 1/2 Study Of Pneumococcal Conjugate Vaccine

Merck & Co., Inc. (MRK) said it has presented positive results from the phase 1/2 study, dubbed as V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company's investigational 21-valent pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve adults 18-49 years of age and 50 years of age and older.

In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to PNEUMOVAX23 (Pneumococcal Vaccine Polyvalent) across age groups.

In the phase 2 part of the study, V116 demonstrated non-inferior immune responses to PNEUMOVAX 23 for all shared serotypes, and superior immune responses for the serotypes included in V116 but not included in PNEUMOVAX 23, based on study-defined criteria. Responses were measured 30 days post-vaccination by serotype-specific opsonophagocytic activity geometric mean titers, a measure of functional antibody activity.

Broad phase 3 clinical program for V116 in vaccine-naïve and vaccine-experienced adults is planned to start in July 2022.

Earlier this year, V116 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. This includes eight serotypes not included in any currently licensed pneumococcal vaccine.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Unemployment data from Spain and producer prices from the euro area are due on Tuesday, headlining a light day for the European economic news. At 2.00 am ET, the National Institute of Statistics is scheduled to issue Romania's producer prices for August. Australia's central bank raised its benchmark rate by a quarter-point to bring inflation back to the target range. The policy board of the RBA, headed by Governor Philip Lowe, decided to lift the cash rate target by 25 basis points to 2.60 percent from 2.35 percent. This was the highest rate since... Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday.
Follow RTT